Clearmind Medicine Inc recorded a cumulative net loss of $-12 million during 12 month ending in the first quarter 2026.
The Healthcare sector has seen employees of 242 other companies achieving higher income per employee. While Clearmind Medicine Inc's total ranking has deteriorated compared to the previous quarter from 3886 to 3905.

What is Income per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Net Income per Employee▼

None ▼

Net Income per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CMND Net Income per Employee	(Jan 31 2026) I. Quarter	(Oct 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter
Y / Y Net Income Change	-	-	-	-	-
Net Income per Employee (TTM) $	-2,079,237	-1,615,410	-1,054,383	-1,403,369	-1,554,739
CMND's Total Ranking	# 3905	# 3886	#	#	#
Seq. Net Income Change	-	-	-	-	-

CMND Company Profile >> Back to CMND Efficiency Comparisons >> Compare CMND Net Income per Employee to its Competitors

CMND Net Income per Employee Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 243
Healthcare Sector	# 636
Overall Market	# 3905

Net Income per Employee Statistics
High	Average	Low
$ -1,712	$ -561,406	$ -1,436,806
(Sep 30 2014)		(Oct 31 2025)

News about Clearmind Medicine Inc Income per employee

Clearmind Medicine Unwavering Progress in the Quest for Alcohol Use Disorder Treatments Amidst Financial Challenges

In a noteworthy development within the biotech landscape, Clearmind Medicine Inc. (Nasdaq: CMND), a Vancouver-based company dedicated to pioneering novel therapeutics for under-treated health issues, has received unanimous endorsement from its independent Data and Safety Monitoring Board (DSMB) to continue its Phase I/IIa clinical trial for CMND-100. This proprietary neuroplastogen, hailed for its non-hallucinogenic properties, is under investigation for its potential to reshape the treatment paradigm for Alcohol Use Disorder (AUD). On November 24, 2025, Clearmind announced that the DSMB had conducted a scheduled interim review and expressed confidence in the next stages of the trial based on promising safety data from its initial cohort. The favorable profile outlined in this top-line data marks a significant validation of Clearmind s innovative approach to addressing AUD, a condition that remains a formidable public health challenge with limited effective treatment options.Dr. David M. Nutt, an esteemed figure in the realm of mental health and substance use research, insists that the successful trial outcomes could signal a new dawn for those grappling with the debilitating effects of alcoholism. With the majority of current treatments falling short of providing comprehensive solutions, the promise of CMND-100 could lead to a breakthrough in enhancing recovery rates and improving patients’ overall quality of life.

Companies with similar Income per Employee for 12 month ending Jan 31 2026, within Healthcare Sector

Income per Employee

Income 12 month ending Jan 31 2026

Number of Employees Jan 31 2026

Date modified: 2026-07-07T10:02:30+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.